BioCryst Pharmaceuticals, Inc. (BCRX)

NMS – Real Time Price. Currency in USD

10.30

-0.04 (-0.44%)

Market open: Aug 12, 2026, 11:38 AM EDT

10.23

-0.11 (-1.06%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors need to pay close attention to BCRX stock based on the movements in the options market lately.

11.08.2026

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion.

05.08.2026

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

05.08.2026

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals NASDAQ: BCRX reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE.

05.08.2026

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.

05.08.2026

BioCryst Reports Second Quarter 2026 Financial Results

— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended June 30, 2026, and provided a business update.

Videos

No Data

There is no data to display

Press releases

05.08.2026

BioCryst Pharmaceuticals, Inc. (BCRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioCryst Pharmaceuticals, Inc. (BCRX)

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

BioCryst Reports Second Quarter 2026 Financial Results

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

BioCryst Reports Second Quarter 2026 Financial Results

Search stocks

BioCryst Pharmaceuticals, Inc. (BCRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioCryst Pharmaceuticals, Inc. (BCRX)

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

BioCryst Reports Second Quarter 2026 Financial Results

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst Reports Second Quarter 2026 Financial Results

Videos

No Data

Press releases

BioCryst Reports Second Quarter 2026 Financial Results